Deepak L Bhatt,Michael Szarek,Bertram Pitt,et al.

Conclusions:In patients with diabetes and chronic kidney disease,with or without albuminuria,sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes,hospitalizations for heart failure,and urgent visits for heart failure than placebo but was associated with adverse events.